RJA
TMDX icon

Raymond James & Associates’s Transmedics TMDX Stock Holding History

Raymond James & Associates’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.31M Buy
27,436
+3,992
+17% +$615K ﹤0.01% 1757
2024
Q2 		$3.53M Buy
23,444
+14,156
+152% +$1.7M ﹤0.01% 1819
2024
Q1 		$687K Buy
9,288
+4,695
+102% +$387K ﹤0.01% 2861
2023
Q4 		$363K Buy
4,593
+851
+23% +$51.3K ﹤0.01% 3158
2023
Q3 		$205K Sell
3,742
-2,079
-36% -$150K ﹤0.01% 3441
2023
Q2 		$489K Sell
5,821
-14,457
-71% -$1.11M ﹤0.01% 2955
2023
Q1 		$1.54M Buy
20,278
+13,094
+182% +$906K ﹤0.01% 2193
2022
Q4 		$443K Buy
7,184
+1,710
+31% +$90.9K ﹤0.01% 2983
2022
Q3 		$228K Buy
+5,474
New +$238K ﹤0.01% 3361
2021
Q2 		– Sell
-8,595
Closed -$357K – 4201
2021
Q1 		$357K Buy
+8,595
New +$265K ﹤0.01% 3246

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Raymond James & Associates's TMDX Position: Q3 2024 in Review

Raymond James & Associates increased its Transmedics (TMDX) stake by 17% in Q3 2024, buying an estimated $615K and bringing the position to 27,436 shares worth $4.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Raymond James & Associates first reported a position in TMDX in Q1 2021 and has held it in 10 quarters since. 373 funds tracked by Wall St. Rank hold TMDX as of Q3 2024.

  • Raymond James & Associates held 27,436 shares of Transmedics worth $4.31M as of Q3 2024.
  • Raymond James & Associates bought 3,992 Transmedics shares in Q3 2024, an estimated $615K.
  • Transmedics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1757 holding.
  • Raymond James & Associates first reported a position in Transmedics in Q1 2021 and has held it in 10 quarters since.
  • 373 funds tracked by Wall St. Rank held Transmedics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.